And who says bladder cancer is limited to humans. I wonder if CxBladder can be adapted for dogs and animals?
http://phys.org/news/2014-06-cancer-...gs-humans.html
Now, wouldn't that boost sales!
Printable View
And who says bladder cancer is limited to humans. I wonder if CxBladder can be adapted for dogs and animals?
http://phys.org/news/2014-06-cancer-...gs-humans.html
Now, wouldn't that boost sales!
cant make up my mind...race 1 at terapa has the the auld Floosie...race 2 has hot in pink and race 3 has fast and georgous ...which one best describes you..ha ha...good to see this thread has returned to normal and the snipping has settled down....money definetly guides peoples principles....some good informative posts...heck i may even invest:t_up:
Hey Snaps clear out your PM - I have something for you
Probably PM full of abuse anyway - just press the delete inbox button
Snapiti - you keep reiterating that PEB has had poor sales traction however I am wondering as to how you have objectively quantified this?
In terms of the bio-tech / cancer test assay market how exactly do you define what constitutes great, good or poor sales traction for new entrants like PEB?
Are you basing this on comparing PEB's performance to comparable companies or are you simply stating that their performance was "poor" due to their low level of of absolute sales?
I.e whats your rationale?
Or you could say the first USA sale was made on the 18 of October 2013 and the last sale for the period was in late Jan or Feb depending on their terms of trade. Take out Christmas and your looking at 170 sales in a period of 3-4 months in the USA or 1-2 tests sold each day, I don't think the period of time is great enough to determine either way.